Stock Scorecard
Stock Summary for PTC Therapeutics Inc (PTCT) - $86.25 as of 11/26/2025 8:50:12 PM EST
Total Score
11 out of 30
Safety Score
57 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PTCT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PTCT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PTCT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PTCT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PTCT (57 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 1 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for PTCT
Company Overview |
|
|---|---|
| Ticker | PTCT |
| Company Name | PTC Therapeutics Inc |
| Country | USA |
| Description | PTC Therapeutics, Inc. is a leading biopharmaceutical company headquartered in South Plainfield, New Jersey, specializing in the development of innovative therapies for rare genetic disorders. With a strong emphasis on RNA modulation and small molecule therapeutics, PTC has built a compelling pipeline of product candidates that address critical unmet medical needs. The company's commitment to transformative treatments establishes it as a significant player in the rare disease market, where its pioneering solutions aim to enhance patient outcomes and address the challenges faced by those with serious, underserved conditions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 86.25 |
| Price 4 Years Ago | 39.83 |
| Last Day Price Updated | 11/26/2025 8:50:12 PM EST |
| Last Day Volume | 15,305,636 |
| Average Daily Volume | 1,169,187 |
| 52-Week High | 81.16 |
| 52-Week Low | 35.95 |
| Last Price to 52 Week Low | 139.92% |
Valuation Measures |
|
| Trailing PE | 9.28 |
| Industry PE | 43.18 |
| Sector PE | 88.38 |
| 5-Year Average PE | -3.80 |
| Free Cash Flow Ratio | 10.29 |
| Industry Free Cash Flow Ratio | 13.63 |
| Sector Free Cash Flow Ratio | 28.18 |
| Current Ratio Most Recent Quarter | 2.32 |
| Total Cash Per Share | 8.38 |
| Book Value Per Share Most Recent Quarter | -1.95 |
| Price to Book Ratio | 1,743.27 |
| Industry Price to Book Ratio | 33.42 |
| Sector Price to Book Ratio | 32.98 |
| Price to Sales Ratio Twelve Trailing Months | 3.60 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.78 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.65 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 80,288,000 |
| Market Capitalization | 6,924,840,000 |
| Institutional Ownership | 104.77% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 42.02% |
| Reported EPS 12 Trailing Months | 8.60 |
| Reported EPS Past Year | 9.41 |
| Reported EPS Prior Year | -4.20 |
| Net Income Twelve Trailing Months | 751,723,000 |
| Net Income Past Year | -363,295,000 |
| Net Income Prior Year | -626,604,000 |
| Quarterly Revenue Growth YOY | 7.20% |
| 5-Year Revenue Growth | 21.32% |
| Operating Margin Twelve Trailing Months | 1.65% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 672,617,000 |
| Total Cash Past Year | 779,709,000 |
| Total Cash Prior Year | 594,001,000 |
| Net Cash Position Most Recent Quarter | 386,604,000 |
| Net Cash Position Past Year | -1,329,658,000 |
| Long Term Debt Past Year | 2,109,367,000 |
| Long Term Debt Prior Year | 1,903,996,000 |
| Total Debt Most Recent Quarter | 286,013,000 |
| Equity to Debt Ratio Past Year | -1.09 |
| Equity to Debt Ratio Most Recent Quarter | -1.20 |
| Total Stockholder Equity Past Year | -1,098,071,000 |
| Total Stockholder Equity Prior Year | -818,555,000 |
| Total Stockholder Equity Most Recent Quarter | -155,758,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 698,997,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 8.71 |
| Free Cash Flow Past Year | -181,937,000 |
| Free Cash Flow Prior Year | -279,037,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 2.86 |
| MACD Signal | 2.57 |
| 20-Day Bollinger Lower Band | 39.17 |
| 20-Day Bollinger Middle Band | 59.05 |
| 20-Day Bollinger Upper Band | 78.93 |
| Beta | 0.49 |
| RSI | 74.36 |
| 50-Day SMA | 52.03 |
| 150-Day SMA | 41.32 |
| 200-Day SMA | 41.26 |
System |
|
| Modified | 11/25/2025 7:11:01 AM EST |